Pharmaceutical Pfizer Inc. announced that it has filed a request with US health regulators for authorize their vaccine against the coronavirus, covid-19, under the figure of emergency use, a crucial step to spread the doses and contribute to immunization that helps stop the pandemic.
The proceedings before the Food and Drug Administration (FDA) comes just days after Pfizer, along with its German partner BioNtech, reported that the final results of their trial yielded a percentage of 95 percent effectiveness, without major biosecurity concerns.
Shares of Pfizer were up two percent and BioNTech’s five percent on news that the vaccine could be available soon, raising hope for the end of a pandemic that has claimed more than a quarter of a million lives in the United Statesand more than 1.3 million worldwide.
At the company expects FDA approval of emergency use authorization by mid-December, after which you could start sending doses almost immediately. Pfizer said it expects to have 50 million doses of vaccines ready this year, enough to protect 25 million people.